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Summary Shigella species isolated from stool samples of symptomatic patients
of all age groups at the Mubarak Al Kabir Hospital and Infectious Diseases Hos-
pital, Kuwait and Tawam Hospital, UAE during a 2-year period were investigated
for their susceptibility to tigecycline and several other antibiotics by determining
the minimum inhibitory concentrations (MICs) using the E test method. A total of
100 and 42 strains were collected from UAE and Kuwait, respectively. The extent
of drug resistance in the Shigella spp. isolates from these two countries was ana-
lyzed by criteria recommended by the Clinical and Laboratory Standards Institute
(CLSI). Amikacin, cefotaxime, cefuroxime, ciproﬂoxacin, imipenem, meropenem,
piperacillin-tazobactam and tigecycline had excellent activities against all iso-
lates from UAE and Kuwait with MIC90s of 12, 0.094, 4, 0.012, 0.25, 0.032, 3 and
0.25g/ml and 4, 1, 4, 0.125, 0.38, 0.19, 3 and 0.25g/ml, respectively. Half
of all isolates from both countries were resistant to ampicillin. None of the iso-
lates in Kuwait was resistant to amoxicillin—clavulanic acid compared with 22%
in UAE. Resistance to chloramphenicol was recorded in 50 and 36% of the iso-
lates in Kuwait and UAE, respectively. The percentages of non-susceptibility to
trimethoprim-sulfamethoxazole and tetracycline were very high in Kuwait and UAE
(76% vs. 92% and 76% vs. 98%, respectively). Notably, one isolate, S. ﬂexneri, from
UAE had reduced susceptibility to ciproﬂoxacin (MIC, 0.25g/ml). Four (2.8%) of
the isolates were ESBL producers by the E test ESBL method but could not be con-
ﬁrmed by PCR using primers for blaCTX-M, blaSHV and blaTEM. In conclusion, Shigella
spp. isolated from symptomatic patients in Kuwait and the UAE demonstrated high
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rates of resistance to the ﬁrst-line antibiotics but very susceptible to the carbapen-
ems, cephalosporins, ﬂuoroquinolones and tigecycline. Tigecycline holds promise as
a potential drug of choice for the therapy of severe shigellosis.
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ampicillin ≤8g/ml, amoxicillin—clavulanic acid
≤8/4g/ml, cefotaxime ≤8g/ml, ceftriaxone
≤8g/ml, cefuroxime ≤8g/ml, chloramphenicol© 2009 King Saud Bin Ab
Ltd. All rights reserved.
Introduction
Shigella species is an important public health
problem throughout the world both in developing
and developed countries. Shigellosis, the infec-
tion caused by Shigella spp., is regarded as a
major cause of diarrhoea with high morbidity and
mortality especially in children. Shigella infec-
tions can lead to mild self-limiting diarrhoea to
severe dysentery. Complications are often seen
in children, elderly, malnourished and immuno-
suppressed patients. Although conservative oral
rehydration therapy may be adequate treatment
for milder cases of infections caused by Shigella
spp. other than S. dysenteriae type 1, antimicro-
bial chemotherapy is often required for treating
shigellosis in general, and cases of S. dysenteriae
type 1 in particular. However, since S. dysenteriae
type 1 produces Shiga toxin, the use of antibiotics
may become a dilemma. Effective and appropri-
ate antimicrobial chemotherapy may reduce the
duration of fecal excretion of the micro-organisms,
reduce the duration of the illness and reduce the
spread of the infection [1]. Ampicillin was the drug
of choice until the mid-1980s when it was replaced
by trimethoprim-sulfamethoxazole and nalidixic
acid [2]. Antimicrobial resistance of Shigella spp.
is increasing because of antimicrobial agents that
are used widely in clinical medicine especially
in developing countries [3,4]. Multi-drug resistant
Shigella spp. have been reported including resis-
tance to ﬂuoroquinolones and the third-generation
cephalosporins such as cefotaxime and ceftriaxone,
in which antimicrobial therapy has become very
limited [4,5]. Third-generation cephalosporins or
ciproﬂoxacin are the main drugs used for treating
invasive Shigella infection in Kuwait and UAE.
The aim of the present study is to evaluate the
antimicrobial susceptibility of clinical isolates of
Shigella spp. in Kuwait and UAE and determine the
extent of resistance problem in the two countries.
Materials and methodsBacterial strains
In Kuwait, Shigella spp. isolated from the stool
samples of patients with acute diarrhoea were
≤
≤
≤
tziz University for Health Sciences. Published by Elsevier
ollected between April 2003 and March 2005
rom Mubarak Al Kabir Hospital, Jabriya and Infec-
ious Disease Hospital while in the UAE, Shigella
pp. isolated from patients with similar symptoms
ttending Tawam Hospital, Al Ain were collected
etween January 2003 and December 2004. Only
he Shigella spp. isolated from stool cultures were
valuated. There were no replicate strains in this
tudy. The isolates were then stored at −80 ◦C
ntil used. Isolates from Kuwait were identiﬁed at
he Clinical Microbiology Laboratory of Mubarak Al
abir Hospital, Kuwait by standard methods using
utomated Vitek II system (BioMerieux, Marcy-
’Eoile, France) and those from UAE by API 20E
BioMerieux, France) in the Microbiology Laboratory
f Tawam Hospital, Al Ain, UAE. The strains were
dentiﬁed to species levels using serological latex
gglutination (Denka Seiken UK Ltd., Derbyshire,
K).
ntimicrobial susceptibility testing
he susceptibility testing was performed at
he Anaerobe/Hospital Infection Laboratory,
epartment of Microbiology, Faculty of Medicine,
uwait. All isolates were tested for their sus-
eptibility to the following antibiotics: amikacin,
mpicillin, amoxicillin—clavulanic acid, cefo-
axime, ceftriaxone, cefuroxime, chloramphenicol,
iproﬂoxacin, gentamicin, imipenem, meropenem,
iperacillin-tazobactam, tetracycline, tigecycline,
nd trimethoprim-sulfamethoxazole by deter-
ining the minimum inhibitory concentrations
MICs) using E test (AB Biodisk, Solna, Sweden).
reakpoints for antibiotics used to interpret the
esults of the Shigella spp. were according to
he Clinical and Laboratory Standard Institute [6]
xcept for tigecycline where the US Food and
rug Administration (FDA) breakpoint was applied
Tigacil package insert; Wyeth Pharmaceuticals
nc., Philadelphia, PA, USA). The antibiotic break-
oints used were as follows: amikacin ≤16g/ml,8g/ml, ciproﬂoxacin ≤1g/ml, gentamicin
4g/ml, imipenem ≤4g/ml, meropenem
4g/ml, piperacillin-tazobactam ≤16/4g/ml,
etracycline ≤4g/ml, tigecycline ≤2g/ml
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scherichia coli ATCC 25922 was included in each
un as quality control.
etection of extended-spectrum
-lactamases (ESBL) production
solates inhibited by ≥1g/ml of cefotaxime (CTX)
nd ceftriaxone were investigated for ESBL pro-
uction. For this phenotypic characterization, E
est ESBLmethod using both ceftazidime (CAZ)/CAZ
ombined with clavulanic acid (CA) and CTX/CTX
ombined with CA strips (AB Biodisk, Solna,
weden) was carried out according to the manufac-
urer’s instructions. In-house ESBL-producing and
SBL-negative E. coli were included in the test runs
s positive and negative controls, respectively.
etection of resistance genes
enotypic conﬁrmation of ESBL-positive isolates
as assessed by the PCR technique. Brieﬂy, DNA
xtraction was carried out with the Nucleospin tis-
ue Kit (Macherey-Nagel). PCR ampliﬁcation was
hen carried out to detect the presence of blaCTX-M,
laSHV and blaTEM using the following primers: for
laCTX-M, MA-1 5′-SCS ATG TGC AGY ACC AGT AA-′ and MA-2 5′-CCG CRA TAT GRT TGG TGG TG-3′,
or bla , OS-5 5′-TTA TCT CCC TGT TAG CCA CC-3′SHV
nd OS-6 5′-GAT TTG CTG ATT TCG CTC GG-3′ and
or blaTEM, C 5′-TCG GGG AAA TGT GCG CG-3′ and
5′-TGC TTA ATC AGT GAG GCA CC-3′ [7]. PCR was
arried out as previously described [8].
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Table 1a The minimum inhibitory concentrations (MICs) of
from Kuwait.
Antibiotic (breakpoint, g/ml) Range
Amikacin (16) 1.5—4
Ampicillin (8) 0.5—>256
Amoxicillin—CA (8/4) 1.5—6
Cefotaxime (8) 0.047—1
Ceftriaxone (8) 0.047—1
Cefuroxime (8) 0.75—4
Chloramphenicol (8) 1—>256
Ciproﬂoxacin (1) 0.004—0.125
Gentamicin (4) 2—6
Imipenem (4) 0.023—0.38
Meropenem (4) 0.016—0.19
Piperacillin-taz (16/4) 0.38—3
Tetracycline (4) 1.5—192
Tigecycline (2 0.064—0.25
TRM-SXT (4) 0.19—>32
CA: clavulanic acid; Piperacillin-taz: piperacillin-tazobactam; TRM-ella species 37
esults
acterial isolates
total of 142 Shigella isolates from fecal samples of
atients with gastroenteritis, comprising 100 from
AE and 42 from Kuwait were studied. They were
ade up of 58 (58%) S. ﬂexneri, 36 (36%) S. son-
ei, 2 (2%) S. dysenteriae, 2 (2%) S. boydii and
(2%) Shigella spp. from UAE and those isolated
rom Kuwait were 32 (76.2%) S. ﬂexneri and 10
23.8%) S. sonnei. The overall predominant species
as S. ﬂexneri representing 90 (63.3%) of the total
solates, followed by S. sonnei 46 (32.4%) in both
ountries. Only 1.4% of the total isolates were S.
ysenteriae.
ntimicrobial susceptibility
he susceptibility of Shigella spp. isolated from
uwait and UAE is shown in Tables 1a and 1b.
hey are expressed as the concentration of antibi-
tics that inhibited 50% (MIC50) and 90% (MIC90)
f the isolates. Of the 142 isolates, 71 (50%)
rom both Kuwait and UAE were resistant to ampi-
illin with MIC90 of >256g/ml. The Shigella spp.
solated from UAE were more resistant to tetra-
ycline and trimethoprim-sulfamethoxazole than
hose from Kuwait. Among the UAE isolates, 98
98%) and 92 (92%) were resistant to tetracycline
nd trimethoprim-sulfamethoxazole, respectively,
ompared to 32 (76.2%) and 32 (76.2%), respec-
ively from Kuwait. The MIC90s of tetracycline
128g/ml) and trimethoprim-sulfamethoxazole
>32g/ml) against UAE isolates were very high.
antimicrobials against clinical isolates of Shigella spp.
MIC50 MIC90 No (%) resistant
1.5 4 0 (0)
3 >256 21 (50)
3 6 0 (0)
0.19 1 0 (0)
0.19 0.75 0 (0)
1 4 0 (0)
2 >256 21 (50)
0.006 0.125 0 (0)
2 6 11 (26.2)
0.125 0.38 0 (0)
0.032 0.19 0 (0)
1.5 3 0 (0)
96 128 32 (76.2)
0.064 0.25 0 (0)
>32 >32 32 (76.2)
SXT: trimethoprim-sulfamethoxazole.
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Table 1b The MICs of antimicrobials against clinical isolates of Shigella spp. in UAE
Antibiotic (breakpoint, g/ml) Range MIC50 MIC90 No (%) resistant
Amikacin (16) 2—16 4 12 0 (0)
Ampicillin (8) 1.5—>256 12 >256 50 (50)
Amoxicillin—CA (8/4) 1.5—16 2 12 22 (22)
Cefotaxime (8) <0.016—2 0.032 0.094 0 (0)
Ceftriaxone (8) 0.032—1 0.19 0.094 0 (0)
Cefuroxime (8) 0.032—4 2 4 0 (0)
Chloramphenicol (8) 0.5—>256 4 >256 36 (36)
Ciproﬂoxacin (1) 0.003—0.25 0.008 0.012 0 (0)
Gentamicin (4) 1—6 3 4 6 (6)
Imipenem (4) 0.125—0.5 0.19 0.25 0 (0)
Meropenem (4) 0.016—0.047 0.023 0.032 0 (0)
Piperacillin-taz (16/4) 0.25—16 0.75 3 0 (0)
Tetracycline (4) 3—>256 96 128 98 (98)
0.064 0.25 0 (0)
>32 >32 92 (92)
TRM-SXT: trimethoprim-sulfamethoxazole.
these multi-resistant isolates is shown in Table 2.
According to the resistance pattern proﬁles,
they were assigned into 10 groups of various
combinations. The most common pattern among
isolates from UAE was resistance to tetracycline
and trimethoprim-sulfamethoxazole accounting
for 47.5% of the resistant isolates, followed
by resistance to ampicillin, chloramphenicol,
trimethoprim-sulfamethoxazole and tetracycline,
i.e. 16.3%. A total of 75 (93.8%) isolates were
Table 2 Antibiotic resistance proﬁle of the multi-
resistant clinical isolates of Shigella spp. in UAE and
Kuwait.
Antibiotic resistance
pattern
No (%) of isolates
UAE
(n = 80)
Kuwait
(n = 32)
Amp, TRM-SXT 3 (3.8) 0 (0)
TRM-SXT, Tet 38 (47.5) 11 (34.4)
Amp, C, Tet 3 (3.8) 0 (0)
Amp,TRM-SXT, Tet 8 (10) 0 (0)
Amp, C, TRM-SXT,
Tet
13 (16.7) 11 (34.4)
Amp, C, TRM-SXT,
Amc, Tet
8 (10) 0 (0)
Amp, TRM-SXT, Amc,
Tet
3 (3.8) 0 (0)
Amp, C, Amc, Tet 2 (2.5) 0 (0)
Amp, C, Gn,
TRM-SXT, Amc, Tet
2 (2.5) 0 (0)Tigecycline (2) 0.047—0.5
TRM-SXT (4) 0.047—>32
CA: clavulanic acid; Piperacillin-taz: piperacillin-tazobactam;
However, Kuwaiti isolates were more resistant to
chloramphenicol and gentamicin than the UAE iso-
lates. Among the Kuwaiti isolates, 21 (50%) and 11
(26.2%) were resistant to chloramphenicol and gen-
tamicin, respectively compared with 36 (36%) and
6 (6%) of the UAE isolates. The MIC90 of chloram-
phenicol were each >256g/ml for both countries.
None of the Kuwaiti isolates were resistant to
amoxicillin—clavulanic acid, in contrast to 22 (22%)
resistant isolates from the UAE.
However, all the isolates from both countries
were fully susceptible to amikacin, cefotaxime,
ceftriaxone, cefuroxime, imipenem, meropenem,
piperacillin-tazobactam and tigecycline. The aver-
age MIC90s for the Kuwaiti isolates were as follows:
amikacin 4g/ml, cefotaxime 1g/ml, ceftriax-
one 0.75g/ml, cefuroxime 4g/ml, ciproﬂoxacin
0.125g/ml, imipenem 0.38g/ml, meropenem
0.19g/ml, piperacillin-tazobactam 3g/ml and
tigecycline 0.25g/ml; while for the UAE isolates
they were 12g/ml, 0.094g/ml, 0.094g/ml,
4g/ml, 0.012g/ml, 0.25g/ml, 0.32g/ml,
3g/ml and 0.25g/ml, respectively.
All the isolates from Kuwait and the UAE were
susceptible to ciproﬂoxacin with MIC range of
0.003—0.25g/ml, although only one isolate, S.
ﬂexneri serotype 3, from the UAE demonstrated
reduced susceptibility with MIC 0.25g/ml.
Prevalence of multi-drug resistanceOf the 100 isolates from the UAE, 80 (80%) were
resistant to two or more drugs, especially the
ﬁrst-line antibiotics and 39 (48.8%) were resis-
tant to three or more antibiotics, i.e. multi-drug
resistant isolates (MDR). The distribution of
Amp, C, Gn,
TRM-SXT, Tet
0 (0) 10 (31.3)
Amp: ampicillin; TRM-SXT: trimethoprim-sulfamethoxazole;
Tet: tetracycline; C: chloramphenicol; Gn: gentamicin; Amc:
amoxicillin—clavulanic acid.
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esistant to trimethoprim-sulfamethoxazole and
ther drugs while 42 (52.5%) were resistant to
mpicillin and other antibiotics. In contrast,
2 (76.2%) of the 42 isolates from Kuwait were
esistant to two or more antibiotics of which 21
65.6%) were resistant to three or more antibiotics.
hree categories of resistance patterns emerged
mong the isolates; 11 (34.4%) each were resistant
o trimethoprim-sulfamethoxazole/tetracycline
nd ampicillin/chloramphenicol/trimethoprim-
ulfamethoxazole/tetracycline combinations
hile 10 (31.3%) were resistant to ampicillin/
hloramphenicol/gentamicin/trimethoprim-
ulfamethoxazole/tetracycline combination.
In the UAE, the MDR isolates among individ-
al Shigella spp., were represented mainly by S.
exneri which accounted for 56 (70%) and S. son-
ei, 24 (30%) while in Kuwait the proportion of MDR
solates that were S. ﬂexneri was 32 (100%) and S.
onnei 0 (0%).
revalence of ESBL-producing Shigella
solates
nly 12 (8.5%) isolates were inhibited by ≥1g/ml
f cefotaxime or ceftriaxone and these were
nvestigated for ESBL production. Of these, 4
33.3%) were positive for ESBL phenotypes by both
f the E test ESBL methods (CTX/CTX +CA and
AZ/CAZ +CA). That is, 2.8% of the total isolates
ere ESBL producers. As shown in Table 3, they
ere 3 S. ﬂexneri and 1 S. sonnei; all from the
AE collection. However, ampliﬁed PCR products
f these isolates investigated for bla genes of ESBL
ere negative.
s
d
c
c
Table 3 Susceptibility of four ESBL-producing Shigella spp
Antimicrobial agents Minimum inhibitory concentration
S. ﬂexneri No. 22 S. sonnei
Amikacin 4 8
Ampicillin >256 >256
Cefotaxime 1 2
Cefuroxime 1.5 3
Chloramphenicol 1 2
Ciproﬂoxacin 0.12 0.006
Gentamicin 3 6
TRM-SXT >32 >32
Imipenem 0.125 0.25
Meropenem 0.016 0.047
TRM-SXT: trimethoprim-sulfamethoxazole.
a Serial number.ella species 39
iscussion
. dysenteriae, S. ﬂexneri, S. boydii and S. sonnei
re responsible for the disease known as shigel-
osis. In the 1990s, S. ﬂexneri was the most common
erogroup isolated in Kuwait accounting for 46% of
ll clinical isolates closely followed by S. sonnei
42%) [9]. Data from a surveillance study in the
AE between October 1999—September 2001 and
anuary—May 2002, showed that S. sonnei was more
ommon than S. ﬂexneri with prevalence rates
f 67% and 28%, respectively [10]. In the present
tudy, there was a much higher prevalence of S.
exneri in Kuwait and UAE accounting for 76% and
8%, respectively while prevalence of S. sonnei has
allen considerably to 23% and 36%, respectively,
ver time. This is fairly similar to the prevalence
ata reported in other developing countries such as
ndia [11], Turkey [12], Nigeria [13] and Eritrea [14].
n contrast, the situation in the developed coun-
ries, like USA, shows that S. sonnei is the most
ommon isolates accounting for 80% of all Shigella
pp. [15].
In this study, tigecycline demonstrated an excel-
ent in vitro activity against all isolates from both
ountries. This is a new drug which has only
ecently been introduced for use in Kuwait and
AE. Other drugs with excellent in vitro activities
nclude amikacin, cephalosporins, carbapenems
nd ciproﬂoxacin. However, the impact of overuse
nd misuse of antimicrobial agents in the therapy of
iarrhoea or other infectious diseases have been an
ncrease in antimicrobial resistance, which can be
een with the high resistance rates to the ﬁrst-line
rugs in this study. This ﬁnding is, no doubt, cru-
ial in clinical practice, especially in the developing
ountries.
. to selected antibiotics.
(g/ml)
No. 37 S. ﬂexneri No. 39 S. ﬂexneri No. 41a
8 3
>256 >256
2 1.5
3 2
256 2
0.012 0.006
2 4
>32 >32
0.25 0.19
0.032 0.032
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This study demonstrates that the resistance
rate of Kuwait and UAE isolates to the ﬁrst-
line drugs has changed over the years since
the ﬁrst reports that came out of these coun-
tries [9,10]. For example, in Kuwait, there is an
upward trend in the resistance rates to chlo-
ramphenicol, trimethoprim-sulfamethoxazole and
gentamicin, whereas the resistance rates to ampi-
cillin and amoxicillin—clavulanic acid appear to
have declined slightly. In UAE, ampicillin and
trimethoprim-sulfamethoxazole resistance in the
previous study was 56.6% and 84.9%, respectively
[10] but are 50% and 92% in this study. These lev-
els of resistance to the ﬁrst-line drugs are lower
than that reported in China where the resistance
rates to ampicillin, trimethoprim-sulfamethoxazole
and gentamicin were 64.9%, 94.6% and 62.2% [16].
Streit et al. [17] have also reported very high
level of ampicillin resistance among Shigella iso-
lates in Latin America as 73.6%, and 76% in Europe,
Israel and Turkey, which are much higher than
the 50% rate observed in the current study in
Kuwait and UAE. In 2003, a SENTRY antimicrobial
surveillance program, reported that over 65% of iso-
lates from Latin America and about 66% in Europe,
Israel and Turkey, were resistant to trimethoprim-
sulfamethoxazole [17], a ﬁnding much lower than
the level of resistance among UAE isolates but
slightly lower than that experienced in Kuwait. It
is conceivable that this high level of resistance in
Kuwait is probably due the frequent and uncon-
trolled use of this drug as a ﬁrst-line choice for
the treatment of many infections, including uri-
nary tract infection, respiratory tract infections
and some skin infections (personal observation).
Although chloramphenicol has been banned for gen-
eral use in Kuwait for over two decades there is
an unacceptable high rate of chloramphenicol resis-
tance among the isolates. Part of the explanation
for this ﬁnding may lie in the fact that the major-
ity of the isolates were from patients of South
East Asian countries or from patients who have
visited the region in recent times, where chloram-
phenicol resistant Shigella spp. are highly prevalent
[3,18,19].
All isolates in Kuwait and UAEwere susceptible to
ciproﬂoxacin signalling the fact that ciproﬂoxacin
can be used effectively for the treatment of shigel-
losis in adults in both countries. However, one
S. ﬂexneri serotype 3 with reduced susceptibil-
ity to ciproﬂoxacin (MIC, 0.25g/ml) was detected
in UAE but the clinical signiﬁcance of this ﬁnd-
ing is unclear at this moment although treatment
failure of infections due to Salmonella strains
with reduced susceptibility has been reported [20].
Whether or not similar treatment failure may occur
E
a
E
cW. Jamal et al.
n shigellosis caused by Shigella spp. with reduced
usceptibility to ciproﬂoxacin is unknown. How-
ver, ﬂuoroquinolone-resistant Shigella spp. remain
are although have recently been identiﬁed in S.
ysenteriae isolates from some Asian countries like
angladesh, India and Nepal [21—23], and strains
ith reduced susceptibility (MIC 0.25—1.0g/ml)
ave been reported in UK [24].
The susceptibility to the third-generation
ephalosporins, e.g. cefotaxime and ceftriaxone,
emains stable over time as demonstrated by
heir excellent activities against isolates from
oth countries in this study and in previous ones
9,10]. Other investigators have reported similar
rends to ours [12,17]. Therefore, cefotaxime, or
eftriaxone, continues to be an important agent
argeting these pathogens in Kuwait and UAE.
owever, it must be stated that although rare,
ephalosporin-resistant Shigella spp. have been
eported from several countries such as Argentina
25], Israel [26], Lebanon [27], China [16] and USA
28].
There was a very high level of tetracycline
esistance among Shigella spp. isolated from both
ountries although with rates relatively lower in
uwait than UAE (76.2% vs. 98%). One of the reports
ith higher rates than these came from isolates
tudied in Europe, Israel and Turkey (80%) [17].
eports from other countries are considerably much
ower than those demonstrated in ours, such as 52%
n Latin America and 45% in the USA [15].
Resistance to the third-generation
ephalosporins mediated by ESBL enzymes is
rare phenomenon although a few reports have
ppeared in the literature which suggested that
his may be an emerging resistance problem in
higella spp. For instance, CTX-M-type ESBL has
een reported among S. sonnei isolates in Israel
26], China [16], Lebanon [27] and USA [28]. In the
epublic of Korea, Kim et al. [5] found both the
TX-M-type and TEM-type ESBLs in 20 isolates of
. sonnei. In our present study, even though 2.8%
f the isolates were phenotypically conﬁrmed as
SBL-producers by the E test ESBL methods, this
bservation could not be veriﬁed at the molecular
evel by the range of PCR primers used. All the
trains, although showed decreased susceptibil-
ty to extended-spectrum cephalosporins, were
onetheless inhibited by cefotaxime MICs in the
usceptible range. Thus, although unlikely, they
ight have given false-positive results by the E test
SBL methods or perhaps other genes not included
mong the ones tested were responsible for the
SBL production.
In conclusion, treatment for shigellosis is criti-
al in person with severe disease such as children
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r immunosuppressed patient as well as patients
nfected by S. dysenteriae. At this time, the option,
s a result of the data presented in this study,
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